Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03978130 · ClinicalTrials.gov registry record · NA

Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease

A NA study, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
400
Enrollment target

NCT03978130: Completed NA study, sponsored by NYU Langone Health.

NCT03978130 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 400 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03978130, a NA study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
400 participants
Enrollment target

Study Summary

RESILIENT is a phase II, multi-center, prospective, pragmatic randomized clinical trial with blinded assessment of the primary endpoint. This study aims to evaluate whether mHealth-CR improves functional capacity in older adults (age ≥65) with IHD compared with standard traditional cardiac rehabilitation care. A total of 400 eligible patients will be randomized in 3:1 manner to mHealth-CR versus usual care for assessment of primary endpoint. Enrollment will occur over approximately 42 months with an expected minimum of 3 months follow-up per participant.

Primary Outcome

Change in 6MWD, reflective of functional capacity, is measured by the 6-minute walk test (6MWT). The 6-minute walk test (6MWT) is a submaximal exercise test in which the pace is self-selected by the participant. The 6MWT will be performed during baseline hospitalization and at the 3-month follow-up visit by a blinded research nurse. The outcome change in 6MWD is calculated as 3 month 6MWD minus baseline 6MWD.

Interventions

  • OTHER mHealth-CR

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2020-01-09
Est. Completion 2024-04-30
Phase NA
NYU Langone Health

1,164 total trials

What the finished NCT03978130 record still lists

NCT03978130 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 1 intervention - of which mHealth-CR is the first listed.

NCT03978130 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03978130 about?

NCT03978130 is a clinical study titled "Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease". RESILIENT is a phase II, multi-center, prospective, pragmatic randomized clinical trial with blinded assessment of the primary endpoint. This study aims to evaluate whether mHealth-CR improves functional capacity in older adults (age ≥65) with IHD compared with standard traditional cardiac rehabilit...

What is the current status of trial NCT03978130?

This trial is currently completed. It is a NA study. The enrollment target is 400 participants. The study started on 2020-01-09. Estimated completion is 2024-04-30.

What interventions are being tested in trial NCT03978130?

The interventions under investigation include: mHealth-CR (OTHER).

Who is sponsoring clinical trial NCT03978130?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03978130's enrollment target sits among peer trials

400 246th of 2000 higher than 1,734 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03978130, the US trial registry maintained by the National Library of Medicine. NCT03978130 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.